Samil Pharmaceutical Co.,Ltd (KRX:000520)
10,100
+130 (1.30%)
At close: Oct 2, 2025
KRX:000520 Revenue
Samil Pharmaceutical Co.,Ltd had revenue of 53.79B KRW in the quarter ending June 30, 2025, a decrease of -0.93%. This brings the company's revenue in the last twelve months to 217.19B, up 3.06% year-over-year. In the year 2024, Samil Pharmaceutical Co.,Ltd had annual revenue of 219.70B with 11.89% growth.
Revenue (ttm)
217.19B
Revenue Growth
+3.06%
P/S Ratio
0.98
Revenue / Employee
372.53M
Employees
583
Market Cap
213.78B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 219.70B | 23.35B | 11.89% |
Dec 31, 2023 | 196.35B | 16.67B | 9.28% |
Dec 31, 2022 | 179.68B | 45.43B | 33.84% |
Dec 31, 2021 | 134.25B | 11.25B | 9.14% |
Dec 31, 2020 | 123.00B | 1.89B | 1.56% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
LigaChem Biosciences | 148.28B |